| Nome |
# |
|
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS, file e268c4cb-6190-a6b7-e053-3a05fe0adea1
|
193
|
|
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis, file e268c4c7-68d3-a6b7-e053-3a05fe0adea1
|
163
|
|
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis, file e268c4c7-91f3-a6b7-e053-3a05fe0adea1
|
122
|
|
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis, file e268c4c9-bd55-a6b7-e053-3a05fe0adea1
|
75
|
|
Teriflunomide treatment reduces B cells in patients with MS., file e268c4c8-590f-a6b7-e053-3a05fe0adea1
|
69
|
|
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study., file e268c4c6-2da4-a6b7-e053-3a05fe0adea1
|
64
|
|
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases, file e268c4c6-0ce0-a6b7-e053-3a05fe0adea1
|
37
|
|
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study, file e268c4cc-0cda-a6b7-e053-3a05fe0adea1
|
12
|
|
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification., file e268c4c6-232b-a6b7-e053-3a05fe0adea1
|
10
|
|
Assessing upper limb function in Multiple Sclerosis by an engineered glove, file e268c4cc-cc58-a6b7-e053-3a05fe0adea1
|
7
|
|
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review, file 457cfa4e-3207-4d02-ba6f-1d30ba018e94
|
4
|
|
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy, file e268c4c7-29b4-a6b7-e053-3a05fe0adea1
|
4
|
|
Epstein-Barr-negative MS: a true phenomenon?, file e268c4c7-9d81-a6b7-e053-3a05fe0adea1
|
4
|
|
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis, file e268c4c7-b9b3-a6b7-e053-3a05fe0adea1
|
4
|
|
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives, file e268c4cd-50cb-a6b7-e053-3a05fe0adea1
|
4
|
|
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study, file 08e4ab46-3c4b-4281-9e41-46db7c1037f6
|
3
|
|
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose, file c28725be-d951-4015-a4f9-a44ccf4d6c71
|
3
|
|
IL-27 imparts immunoregulatory function to human NK cell subsets., file e268c4c7-65ef-a6b7-e053-3a05fe0adea1
|
3
|
|
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy, file e268c4c9-fded-a6b7-e053-3a05fe0adea1
|
3
|
|
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups, file e268c4cd-fec7-a6b7-e053-3a05fe0adea1
|
3
|
|
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS), file f3ff12b9-2759-4fd4-ba5b-1c39cb89fd0e
|
3
|
|
Caregiver Involvement in MS: Duty or Disruption?, file 8546a8e0-5d63-448f-bdd9-728df92a1147
|
2
|
|
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation, file b08cbbf6-b8d8-47e0-807b-b26b0977d81c
|
2
|
|
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial., file e268c4c6-3100-a6b7-e053-3a05fe0adea1
|
2
|
|
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection., file e268c4c7-6d09-a6b7-e053-3a05fe0adea1
|
2
|
|
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study, file e268c4c9-b075-a6b7-e053-3a05fe0adea1
|
2
|
|
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution, file e268c4ca-5e6d-a6b7-e053-3a05fe0adea1
|
2
|
|
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?, file e268c4ca-9aa1-a6b7-e053-3a05fe0adea1
|
2
|
|
Tailoring B cell depletion therapy in MS according to memory B cell monitoring, file e268c4cd-2cd3-a6b7-e053-3a05fe0adea1
|
2
|
|
High or increasing serum NfL is predictive of impending multiple sclerosis relapses, file e268c4ce-f38f-a6b7-e053-3a05fe0adea1
|
2
|
|
Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience, file 72868655-7d49-49b0-bb27-18bb3da11ff3
|
1
|
|
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome, file e268c4c7-6bbf-a6b7-e053-3a05fe0adea1
|
1
|
|
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks, file e268c4c8-7760-a6b7-e053-3a05fe0adea1
|
1
|
|
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study, file e268c4c8-7764-a6b7-e053-3a05fe0adea1
|
1
|
|
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks, file e268c4c8-8216-a6b7-e053-3a05fe0adea1
|
1
|
|
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation, file e268c4c9-045a-a6b7-e053-3a05fe0adea1
|
1
|
|
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study, file e268c4c9-6165-a6b7-e053-3a05fe0adea1
|
1
|
|
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study, file e268c4c9-692e-a6b7-e053-3a05fe0adea1
|
1
|
|
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report, file e268c4c9-6930-a6b7-e053-3a05fe0adea1
|
1
|
|
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study, file e268c4c9-a28d-a6b7-e053-3a05fe0adea1
|
1
|
|
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes, file e268c4c9-d125-a6b7-e053-3a05fe0adea1
|
1
|
|
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study, file e268c4c9-daee-a6b7-e053-3a05fe0adea1
|
1
|
|
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey, file e268c4c9-f6df-a6b7-e053-3a05fe0adea1
|
1
|
|
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod, file e268c4ca-dcb8-a6b7-e053-3a05fe0adea1
|
1
|
|
A case of thyroiditis during natalizumab therapy for multiple sclerosis, file e268c4cb-24e3-a6b7-e053-3a05fe0adea1
|
1
|
|
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study, file e268c4cb-47f4-a6b7-e053-3a05fe0adea1
|
1
|
|
Cladribine vs other drugs in MS: Merging randomized trial with real-life data, file e268c4cc-ab5d-a6b7-e053-3a05fe0adea1
|
1
|
|
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments, file e268c4cd-284d-a6b7-e053-3a05fe0adea1
|
1
|
|
Magnetic Resonance Imaging Finding of Periodontal and Inferior Alveolar Nerve Inflammation in a Subject With Trigeminal Neuralgia, file e268c4cd-32c9-a6b7-e053-3a05fe0adea1
|
1
|
|
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study, file e268c4ce-2914-a6b7-e053-3a05fe0adea1
|
1
|
|
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies, file e268c4ce-3653-a6b7-e053-3a05fe0adea1
|
1
|
|
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial, file e268c4ce-5a74-a6b7-e053-3a05fe0adea1
|
1
|
|
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis, file e268c4ce-6417-a6b7-e053-3a05fe0adea1
|
1
|
|
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis, file f9166705-15d4-421d-8e0f-f08177a1fdeb
|
1
|
| Totale |
832 |